ATXS Astria Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATXS

Price (delayed)

$9.04

Market cap

$496.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.42

Enterprise value

$321.12M

Highlights
Astria Therapeutics's debt has shrunk by 65% YoY and by 33% QoQ
Astria Therapeutics's equity has increased by 32% QoQ and by 10% YoY
The company's EPS rose by 32% YoY but it fell by 14% QoQ
ATXS's quick ratio is down by 15% YoY but it is up by 6% from the previous quarter
The net income has declined by 41% year-on-year and by 33% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of ATXS
Market
Shares outstanding
54.9M
Market cap
$496.32M
Enterprise value
$321.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$72.89M
EBITDA
-$72.89M
Free cash flow
-$68.47M
Per share
EPS
-$2.42
Free cash flow per share
-$2.27
Book value per share
$6.7
Revenue per share
$0
TBVPS
$8.45
Balance sheet
Total assets
$254.67M
Total liabilities
$11.55M
Debt
$329,000
Equity
$243.12M
Working capital
$239.39M
Liquidity
Debt to equity
0
Current ratio
21.73
Quick ratio
21.34
Net debt/EBITDA
2.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-33.4%
Return on equity
-34.7%
Return on invested capital
-138.7%
Return on capital employed
-30%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATXS stock price

How has the Astria Therapeutics stock price performed over time
Intraday
0.44%
1 week
-14.23%
1 month
-38.71%
1 year
-23.71%
YTD
17.71%
QTD
-35.77%

Financial performance

How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.03M
Net income
-$72.89M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 55% year-on-year and by 32% since the previous quarter
The net income has declined by 41% year-on-year and by 33% since the previous quarter

Growth

What is Astria Therapeutics's growth rate over time

Valuation

What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
1.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 32% YoY but it fell by 14% QoQ
Astria Therapeutics's equity has increased by 32% QoQ and by 10% YoY
The P/B is 3.1% higher than the 5-year quarterly average of 1.3 and 3.1% higher than the last 4 quarters average of 1.3

Efficiency

How efficient is Astria Therapeutics business performance
The ROIC has shrunk by 171% YoY and by 118% QoQ
Astria Therapeutics's return on equity has decreased by 29% QoQ but it has increased by 9% YoY
ATXS's ROA is down by 29% QoQ but it is up by 8% YoY

Dividends

What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATXS.

Financial health

How did Astria Therapeutics financials performed over time
ATXS's total assets is up by 31% QoQ and by 10% YoY
ATXS's total liabilities is up by 23% since the previous quarter and by 23% year-on-year
Astria Therapeutics's debt is 100% lower than its equity
Astria Therapeutics's debt has shrunk by 65% YoY and by 33% QoQ
Astria Therapeutics's equity has increased by 32% QoQ and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.